Time to death from any cause · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Time to death from any cause · patients with non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any cause · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any cause · men with metastatic, hormone‐sensitive prostate cancer
Abiraterone + ADT leads to lower time to death from any cause compared with ADT alone (high certainty).
1 finding from 1 review
Time to death from any cause5
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any causeMedian · clinically localized prostate cancer
Radical prostatectomy probably leads to lower time to death from any causeMedian compared with watchful waiting (moderate certainty).
1 finding from 1 review
Time to death from any causeMedian · clinically localized prostate cancer
Radical prostatectomy showed no clear difference in time to death from any causeMedian compared with active monitoring (moderate certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower time to death from any cause Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from any cause (absolute effects: overall mortality)
It is very uncertain whether whole gland primary cryotherapy changes time to death from any cause (absolute effects: overall mortality) compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · patients with non‐muscle invasive bladder cancer
It is very uncertain whether gemcitabine changes time to death from any cause (absolute effect size estimates based… compared with saline (very low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Impact of extended showed no clear difference in time to death from any cause (absolute effect size estimates based… compared with standard lymph node dissection on overall survival among patients… (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months)
Bacillus Calmette‐Guérin (BCG) showed no clear difference in time to death from any cause (absolute effect size estimates based… compared with mitomycin C (MMC) (low certainty).
1 finding from 1 review
Overall survival (time interval between enrolment in the study and death of the person from any cause) · adults with non‐advanced colorectal cancer treated surgically or with neoadjuvant or adjuvant therapy, or both
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found